[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital General de Mexico\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":150},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,78,102,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100635749","phase-3-comparison-of-ferrous-salt-vs-liposomal-iron-in-adult-women-with-iron-deficiency-anemia-100635749",false,"NCT07556731","Comparison of Ferrous Salt vs. Liposomal Iron in Adult Women With Iron-Deficiency Anemia","IDA","Inclusion Criteria:\n\n* Female patients of reproductive age (15 to 49 years) with a diagnosis of iron-deficiency anemia secondary to dysfunctional uterine bleeding.\n* Patients with iron-deficiency anemia who are treatment-naïve or whose last administration of iron therapy, either oral or parenteral, occurred at least three months prior to enrollment and who continue to have anemia.\n* Patients with a functional oral route.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with abnormal uterine bleeding secondary to cancer\n* Severe intolerance to iron supplementation\n* Patients with gastritis or chronic use of proton pump inhibitors\n* Concomitant treatment with dietary supplements rich in calcium, magnesium, or zinc\n* Patients with endocrine disorders (hypothyroidism, hyperthyroidism)\n* Uncontrolled type 2 diabetes mellitus\n* Associated gastrointestinal bleeding\n* Patients with esophageal disorders","FEMALE","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this study is to compare ferrous salt and liposomal iron for the treatment of iron-deficiency anemia in adult women. The study will also evaluate how well each treatment is tolerated.\n\nThe main questions this study aims to answer are:\n\nDoes liposomal iron increase hemoglobin levels as effectively as ferrous salt?\n\nAre there differences in side effects, especially gastrointestinal symptoms, between the treatments?\n\nDoes dosing ferrous salt every other day improve tolerance compared to daily dosing?\n\nResearchers will compare three oral iron treatment strategies to determine which approach provides the best balance between effectiveness and tolerability.\n\nParticipants will:\n\nBe adult women diagnosed with iron-deficiency anemia\n\nBe randomly assigned to one of three groups:\n\nDaily ferrous salt Ferrous salt taken every other day Daily liposomal iron Take the assigned iron treatment for 3 months Have blood tests at the beginning and end of the study to measure hemoglobin and iron levels Report any side effects or intolerance during treatment",[26,27,28,29],"Iron-deficiency Anemia (IDA)","Hemoglobin","Iron Deficiencies","Adverse Effect",[31,32,33,34,35],"Iron-deficiency anemia treatment comparision","Oral iron dosing","Liposomal iron","Iron replacement therapy","ferritin","NOT_YET_RECRUITING","2026-04-22",{"date":39,"type":40},"2026-04-29","ACTUAL",{"date":42,"type":20},"2026-05-01",{"date":44,"type":20},"2027-07-01",{"name":46,"class":47},"Hospital General de Mexico","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100612781","efficacy-of-dose-adjusted-regimen-on-survival-in-frail-adults-with-acute-lymphoblastic-leukemia-100612781","NCT07258043","Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia","Efficacy on Progression Free Overall Survival of a Dose-Adjusted Regimen in Frail Adult Patients With Acute Lymphoblastic Leukemia","EPOCH","Inclusion Criteria:\n\n* Diagnosed with acute lymphoblastic leukemia (ALL) according to the World Health Organization (WHO) criteria\n* Older than 18 years old\n* ECOG Performance Status Scale \\>1 or the Karnofsky Performance Status (KPS) \\\u003C80%.\n* Comorbidities: diabetes mellitus, arterial hypertension, thrombotic events, endocrine disorders, or any condition that hinders the administration of full-dose chemotherapy.\n* Toxicity prior to a standard chemotherapy regimen.\n* Both genders\n* Over 18 years of age\n* No upper age limit\n* Signed informed consent\n\nExclusion Criteria:\n\n´- Patients refractory to induction treatment\n\n* Patients who have previously received a low-intensity regimen due to comorbidities\n* Biphenotypic leukemia\n* CNS involvement at diagnosis requiring radiotherapy\n* Patients whose survival is expected to be less than 48 hours due to leukemiarelated complications\n* Patients with a history of ischemic or hemorrhagic stroke or severe neurological deterioration\n* Pregnant patients","ALL",{"count":59,"type":20},45,"1 Year","OBSERVATIONAL","Acute lymphoblastic leukemia (ALL) is characterized by the abnormal proliferation of immature precursor cells, disrupting normal hematopoiesis and causing severe anemia and thrombocytopenia due to genetic mutations. Conventional treatment with intensive chemotherapy is limited for elderly patients or those with comorbidities, adversely affecting their survival. In Mexico, alongside a higher incidence, treatment-related complications are more frequent, particularly with drugs such as asparaginase or anthracyclines, which limits therapeutic efficacy. The transition to infusion-based therapies promises to reduce these complications, improve treatment tolerance, and optimize clinical outcomes, marking a significant advancement in the management of this disease. Modifying treatment regimens toward infusion therapies has the potential to significantly reduce adverse complications, enhance treatment tolerance, and ultimately improve clinical outcomes for patients who cannot benefit from conventional intensive regimens. This approach not only aims to optimize treatment effectiveness but also to minimize associated risks, thus representing an important advancement in the management of acute lymphoblastic leukemia in clinical settings such as those in Mexico",[64,65,66],"Acute Lymphobkastic Leukemia","Leukemia","Overall Survival",[68,55],"acute lymphoblastic leukemia","RECRUITING","2025-11-26",{"date":72,"type":40},"2025-12-02",{"date":74,"type":40},"2025-07-23",{"date":76,"type":20},"2026-07-26",{"name":46,"class":47},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":57,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":90,"studyType":61,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":48},"100565928","diagnostic-performance-of-controlling-nutritional-status-as-a-nutritional-screening-tool-in-patients-with-inflammatory-bowel-disease-100565928","NCT06648551","Diagnostic Performance of Controlling Nutritional Status as a Nutritional Screening Tool in Patients With Inflammatory Bowel Disease","Diagnostic Performance of CONUT as a Nutritional Screening Tool in Patients With Inflammatory Bowel Disease","CONUT","Inclusion Criteria:\n\n* Age 18 years and older\n* Gender unspecified\n* Histologically confirmed Ulcerative Colitis\n* Diagnosis confirmed by a specialist physician\n\nExclusion Criteria:\n\n* Patients with any amputation or prosthesis\n* Patients with a pacemaker\n* Patients with any neoplasm\n* Pregnancy or lactation\n* With comorbidities such as diabetes, hypertension, heart failure, thyroid problems",true,"80 Years",{"count":89,"type":20},60,"4 Years","The objective of this observational study is to determine the diagnostic performance of CONUT as a nutritional screening tool in patients with Inflammatory Bowel Disease. The main questions to be answered are:\n\nWhat is the sensitivity and specificity of CONUT as a nutritional screening tool in patients with Inflammatory Bowel Disease?\n\nThe participants will:\n\nUndergo body composition analysis and a medical history review to understand the characteristics of their current condition, apply the GLIM criteria, and conduct their nutritional assessment.",[93],"Inflammatory Bowel Disease 5","2024-10-16",{"date":96,"type":40},"2024-10-18",{"date":98,"type":40},"2023-10-28",{"date":100,"type":20},"2027-10-28",{"name":46,"class":47},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":57,"minAge":17,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":48},"100537943","two-schemes-response-in-multiple-myeloma-100537943","NCT06284395","Two Schemes Response in Multiple Myeloma","Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study","Inclusion Criteria:\n\n* clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs.\n\nExclusion Criteria:\n\n* Incomplete clinical records\n* Clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues\n* Clinical records of patients who presented severe sepsis before the beginning of either treatment","90 Years",{"count":111,"type":20},83,"Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.",[114,115],"Response, Acute Phase","Survivorship",[117,118,119,120,121],"Multiple Myeloma","Bortezomib","Thalidomide","Acute Phase Response","Survival","2024-09-30",{"date":124,"type":40},"2024-10-02",{"date":126,"type":40},"2023-11-20",{"date":128,"type":20},"2024-10-30",{"name":46,"class":47},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":57,"minAge":17,"maxAge":87,"enrollmentInfo":137,"targetDuration":139,"studyType":61,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":48},"100561423","effect-of-clinical-and-biochemical-variables-over-morbidity-and-mortality-in-alcohol-withdrawal-syndrome-patients-100561423","NCT06589973","Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients","IImpact of Clinical and Biochemical Variables on Mortality and Morbidity of Patients With Alcohol Withdrawal Syndrome Under Treatment According to the CIWA-AR Scale\"","Inclusion Criteria:\n\n* Clinical records of patients, both genders, over 18 years of age with Alcohol Withdrawal Syndrome according to the criteria for alcohol withdrawal.\n* Clinical records of candidates for admission for neurological monitoring and with criteria for use of sedative drugs according to the CIWA-Ar scale\n* Clinical records of patients containing the CIWA-Ar scale score at diagnosis\n\nExclusion Criteria:\n\n* Clinical records of patients who already have a history of seizures or epilepsy\n* Clinical records of diabetic patients with diabetic ketoacidosis\n* Clinical records of patients who have not received any type of sedative treatment\n* Clinical records of patients with chronic liver failure or liver cirrhosis\n* Clinical records of patients with chronic liver disease with signs of hepatic encephalopathy\n* Clinical records of patients with related toxic-alcoholic hepatitis\n* Clinical records of patients with a life expectancy of less than 24 hours due to associated complications such as head trauma or other associated complications\n* Clinical records of patients who require intubation and mechanical ventilation upon admission\n* Clinical records of patients who have a vascular event that modifies the neurological evaluation\n* Clinical records of patients who before admission show psychomotor alteration or neurological deterioration that modifies the neurological evaluation such as the presence of Wernicke's encephalopathy",{"count":138,"type":20},195,"6 Months","The goal of this observational study is to describe the impact measured through the Odds Ratio (OR) of different variables of clinical and biochemical alterations on the duration of the syndrome alcohol withdrawal patients measured in days of symptoms and stay; it could include any patients with a diagnosis of admission of alcohol withdrawal syndrome (AWS) who have been treated in the department of Internal Medicine for 5 years.\n\nThe main question it aims to answer is: What is the relationship between the different clinical, biochemical, and hematic factors on the duration of symptoms, morbidity, and mortality in individuals with alcohol syndrome withdrawal?\n\n• If the patient has a greater number of risk factors, such as advanced age, a long and chronic history of alcohol consumption, the type of distillate consumed, as well as the deterioration of liver function and presence of leukocytosis and neutrophilia, then it is postulated that the duration of alcohol withdrawal syndrome will be longer.\n\nClinical records will be used to describe the proportion of complications associated with alcohol withdrawal syndrome including pneumonia bronchial aspiration, seizures, need for mechanical ventilation, digestive tract hemorrhage, toxic-alcoholic hepatitis, and pancreatitis.",[142],"Alcohol Withdrawal Syndrome","2024-09-09",{"date":145,"type":40},"2024-09-19",{"date":143,"type":20},{"date":148,"type":20},"2025-02-28",{"name":46,"class":47},""]